跳至主導覽 跳至搜尋 跳過主要內容

Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis

  • Yi Shu Huang
  • , Wen Yi Tseng
  • , Felix I.L. Clanchy
  • , Louise M. Topping
  • , Joy Ogbechi
  • , Kay McNamee
  • , Dany Perocheau
  • , Nien Yi Chiang
  • , Peter Ericsson
  • , Anette Sundstedt
  • , Zhong Tian Xue
  • , Leif G. Salford
  • , Hans Olov Sjögren
  • , Trevor W. Stone
  • , Hsi Hsien Lin
  • , Shue Fen Luo
  • , Richard O. Williams*
  • *此作品的通信作者
  • University of Oxford
  • Chang Gung Memorial Hospital
  • Lund University
  • Idogen AB

研究成果: 期刊稿件 › 文章 › 同儕審查

32 引文 斯高帕斯(Scopus)

摘要

Chronic inflammatory diseases like rheumatoid arthritis are characterized by a deficit in fully functional regulatory T cells. DNAmethylation inhibitors have previously been shown to promote regulatory T cell responses and, in the present study, we evaluated their potential to ameliorate chronic and acute animal models of rheumatoid arthritis. Of the drugs tested, decitabine was the most effective, producing a sustained therapeutic effect that was dependent on indoleamine 2,3-dioxygenase (IDO) and was associated with expansion of induced regulatory T cells, particularly at the site of disease activity. Treatment with decitabine also caused apoptosis of Th1 and Th17 cells in active arthritis in a highly selective manner. The molecular basis for this selectivity was shown to be ENT1, a nucleoside transporter, which facilitates intracellular entry of the drug and is upregulated on effector T cells during active arthritis. It was further shown that short-term treatment with decitabine resulted in the generation of a population of regulatory T cells that were able to suppress arthritis upon adoptive transfer. In summary, a therapeutic approach using an approved drug is described that treats active inflammatory disease effectively and generates robust regulatory T cells with the IDO-dependent capacity to maintain remission.

原文英語
文章編號e2100939118
期刊Proceedings of the National Academy of Sciences of the United States of America
卷118
發行號19
DOIs
出版品狀態已出版 - 11 05 2021

文獻附註

Publisher Copyright:
© 2021 National Academy of Sciences. All rights reserved.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis」主題。共同形成了獨特的指紋。

引用此